Floatz logo

Ipilimumab

Stage II Vulvar Cancer AJCC v7

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Stage II Vulvar Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B
Octreotide Pamoate
Alliance for Clinical Trials in Oncology
Phase 3B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
Durvalumab
M.D. Anderson Cancer Center
Phase 2B

View all 34 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →